Immunotherapy for cancer treatment during pregnancy. Issue 12 (December 2021)

• Record Type: Journal Article
• Authors: Borgers, Jessica S W; Heimovaara, Joosje H; Cardonick, Elyce; Dierickx, Daan; Lambertini, Matteo; Haanen, John B A G; Amant, Frédéric
• Is Part Of: Lancet oncology. Volume 22:Issue 12(2021)
• Page Start: e550
• Page End: e561
• Publication Date: 2021-12
• Subjects: Oncology -- Periodicals; Neoplasms -- Periodicals; Cancérologie -- Périodiques; Oncologie; Oncology; Periodicals; Electronic journals; 616.994005
• DOI: 10.1016/S1470-2045(21)00525-8
• Languages: English
• ISSNs: 1470-2045

Abstract

Summary: Immunotherapy has greatly improved outcomes for subgroups of patients with cancer. As indications keep expanding, there is an unmet need to gain a better understanding of the effect of these therapies on pregnancy and fertility. During pregnancy, substantial adaptations occur in the maternal immune system to maintain protection against pathogens while avoiding detrimental reactions to the semi-allogeneic fetus. The pathways involved in the establishment of this fetomaternal tolerance can be hijacked by cancers. Immunotherapies that target these inhibitory pathways, or that directly interact with the regulatory immune cells involved in tolerance mechanisms, might therefore result in complications during pregnancy. Similarly, by activating the patient's immune system with immunotherapy, a broad range of immune-related adverse events can occur that could negatively affect the fetus or impede a future desired pregnancy. This Review summarises preclinical and clinical data related to the use of immunotherapy during pregnancy, including all approved immune checkpoint inhibitors, recombinant cytokines, cell therapies, vaccines, and immunomodulatory drugs.